Eureka raises $60M series D

Cancer company Eureka Therapeutics Inc. (Emeryville, Calif.) raised $60 million in a series D round led by existing investor Acorn Pacific Ventures. New investor GP Capital also participated, as did all existing major investors.

This quarter, Eureka expects to begin a Phase I trial of its cell therapy ET190L1-ARTEMIS in patients with relapsed and refractory CD19-positive non-Hodgkin's lymphoma (NHL). The therapy uses T cell receptor (TCR)-like antibodies to target CD19...